According tomedia, one of the problems with the new coronavirus is that some people will experience more severe symptoms, especially the elderly and people with other diseases. This usually involves respiratory problems and may require oxygen therapy, including invasive ventilation. Serious complications of the new crown can cause some patients to die, which is why new coronavirus testing is so important. The earlier COVID-19 is diagnosed, the faster treatment can begin. Doctors studying coVID-19 pathology have found ways to reduce the risk of complications. The methodtheys they are testing can provide a way to predict which patients may be prone to severe respiratory problems.
Doctors in the UK are testing a T-cell scheme that can help them predict serious cases and provide effective treatment. In addition, researchers from the U.S. Air Force Research Laboratory (AFRL) believe they can reuse a tool for bomb detection to identify chemicals that show serious COVID-19 complications.
Air Force researchers have designed a small gas chromatograph (micro-GC) that can detect explosives and chemical weapons remotely. A report published in medical letters says the tool could be reused for the detection of industrial toxins, pollutants and narcotics. The system will also detect other substances, including nuclear material, in the presence of “important backgrounds and interferences.” In other words, the system can analyze the composition of the air and look for specific chemicals.
The system was developed under the American Intelligence Advanced Research Projects Agency (IARPA) High-Performance Low-Performance Interrogation Molecular Analyzer (MAEGLIN) program. The researchers believe the same tool could be used to analyze the air breathed by PATIENTs with COVID-19 and try to detect acute respiratory syndrome (ARDS), a respiratory complication associated with many COVID-19 deaths. Symptoms alone are not sufficient to predict whether symptoms in patients with moderate COVID-19 will worsen. The University of Michigan has partnered with AFRL and IARPA to develop a MAEGLIN micro GC breathalyser device that can look for ARDS recognizers.
This diagram shows how diseases are identified by the pattern of compounds detected in the exhaled exhalation. Gas chromatography is an analytical technique that separates the chemical components in an air sample into different components, and retention time (the time it takes for a particular compound to pass through the column) is a recognition feature of each compound.
“The goal of the MAEGLIN program is not to develop a medical device, but to use it as a means for autonomous environmental gas monitoring,” said Dr Robert Bedford, an AFRL researcher. “However, the technology shows the future of medical applications, and we see opportunities to use them for emergency needs during the global pandemic. “
The breathalyser will look for the chemical characteristics of ARDS and provide a negative prognosis warning of the disease. The MAEGLIN unit was modified in less than a week and four redesigned prototypes of the unit were developed. The university began using the gadget in non-military ICUs, with a control group of COVID-19 ARDS patients and healthy adults.
It’s too early to see how effective it will be, but it’s promising. If researchers can come up with a non-invasive way to analyze the patient’s gas data and predict the severity of coVID-19 cases, doctors will have more time to prepare treatments that may avoid severe respiratory distress.
In addition, the National Institutes of Health (NIH) has funded tests of a suitcase-sized gas chromatograph for the same purpose. The trial included 20 non-COVID ARDS patients, because ARDS is a phenomenon that can occur in other conditions. MAEGLIN’S EFFORTS SHOULD BE MORE ACCURATE BECAUSE IT USES MACHINE LEARNING ALGORITHMS TO PROVIDE RESULTS.